Malignant Histiocytosis With PD-L1 Expression—Dramatic Response to Nivolumab

Kharroubi, Dris; Vozy, Aurore; Spano, Jean‐Philippe; Haroche, Julien; Émile, Jean-François

doi:10.1016/j.mayocp.2022.05.012

Cited by 4 publications

(2 citation statements)

References 5 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…exhibiting a stroma rich in histiocytes are mistaken for MH. It is important to correctly diagnose an MH since it requires a particular therapeutic management and sometimes immediate treatment 13–16 …”

Section: Discussionmentioning

confidence: 99%

“…It is important to correctly diagnose an MH since it requires a particular therapeutic management and sometimes immediate treatment. [13][14][15][16] To our knowledge, PU.1 is the only exclusively nuclear marker that can be used to identify a histiocytic origin. OCT2 is another nuclear marker, which is expressed in B-lymphocytes, in B-cell lymphomas, and in some anaplastic large cell lymphomas, 17 was also reported to be positive in some histiocytoses.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

et al. 2023

Self Cite

View full text Add to dashboard Cite

Aims The aim was to test the expression of PU.1 on different types of histiocytoses and to test the utility of PU.1 in confirming or excluding a histiocytic origin in tumour samples with suspicion of histiocytosis. Methods and Results We analysed 66 biopsies of nonmalignant histiocytoses represented by Langerhans‐cell histiocytosis (n = 13), Erdheim–Chester disease (ECD) (n = 19), Rosai–Dorfman disease (RDD) (n = 14), mixed ECD‐RDD (n = 3), ALK‐positive histiocytosis (n = 6), and juvenile xanthogranuloma (n = 11). All cases were positive for PU.1 in reactive and neoplastic histiocytes. In addition, 39 cases of tumours with high‐grade cytological atypia were referred to our center as suspicion of malignant histiocytosis/histiocytic sarcoma and only 18 were confirmed. Indeed, more than half of these tumours (21/39) were either undifferentiated malignant tumours with a stroma rich in histiocytes, diffuse large B‐cell lymphoma, or high‐grade dedifferentiated liposarcoma. PU.1 was useful to distinguish between the negativity of large atypical nuclei and the positivity of stromal reactive histiocytes. Conclusion PU.1 is expressed by all types of histiocytosis. It distinguishes histiocytosis from histiocyte‐rich tumours with an easy interpretation due to its sharp nuclear staining. Its negativity in lesional/tumour cells in histiocyte‐like lesions is useful to eliminate a histiocytosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Doxorubicin/nivolumab/trametinib

2022

Reactions Weekly

View full text Add to dashboard Cite

Long-Term Remission with Novel Combined Immune-Targeted Treatment for Histiocytic Sarcoma Accompanied by Follicular Lymphoma: Case Report and Literature Review

Zhang,

Xiao,

Fang

et al. 2024

IJMS

View full text Add to dashboard Cite

Histiocytic sarcoma (HS) is an extremely rare but aggressive hematopoietic malignancy, and the prognosis has been reported to be rather unfavorable with a median overall survival of merely 6 months. We presented a 58-year-old female patient complaining of abdominal pain and fever, who was admitted to our institution in September 2021. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET/CT) scan showed enlargement of generalized multiple lymph nodes. Subsequently, laparoscopic retroperitoneal lesion biopsy and bone marrow aspiration were performed. The pathological findings indicated the diagnosis of HS concurrent with follicular lymphoma. The immunohistochemistry (IHC) staining of the tumor lesion revealed a high expression of CD38 and PD-L1 proteins. Furthermore, KRAS gene mutation was identified by means of next-generation sequencing. The patient exhibited poor treatment response to both first- and second-line cytotoxic chemotherapies. Therefore, she underwent six cycles of Daratumumab (anti-CD38 monoclonal antibody), Pazopanib (multi-target receptor tyrosine kinases inhibitor) combined with third-line chemotherapy, followed by involved-site radiotherapy and maintenance therapy with the PD-1 inhibitor Tislelizumab. Long-term partial remission was finally achieved after multi-modality treatment. Duration of remission and overall survival reached 22 and 32 months, respectively. Our case indicated that immuno-targeted treatment coupled with chemotherapy and radiotherapy might constitute a potential therapeutic option for HS.

show abstract

Malignant Histiocytosis With PD-L1 Expression—Dramatic Response to Nivolumab

Cited by 4 publications

References 5 publications

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

Doxorubicin/nivolumab/trametinib

Long-Term Remission with Novel Combined Immune-Targeted Treatment for Histiocytic Sarcoma Accompanied by Follicular Lymphoma: Case Report and Literature Review

Contact Info

Product

Resources

About